Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Beigene Ltd Ads (BGNE)

Beigene Ltd Ads (BGNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,766,415
  • Shares Outstanding, K 48,022
  • Annual Sales, $ 198,220 K
  • Annual Income, $ -673,770 K
  • 60-Month Beta 1.18
  • Price/Sales 45.28
  • Price/Cash Flow N/A
  • Price/Book 6.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -4.51
  • Number of Estimates 4
  • High Estimate -2.47
  • Low Estimate -5.35
  • Prior Year -4.52
  • Growth Rate Est. (year over year) +0.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
179.59 +1.55%
on 12/10/19
210.35 -13.30%
on 11/25/19
-17.06 (-8.55%)
since 11/08/19
3-Month
114.41 +59.41%
on 10/10/19
210.35 -13.30%
on 11/25/19
+54.93 (+43.10%)
since 09/10/19
52-Week
108.00 +68.87%
on 01/03/19
210.35 -13.30%
on 11/25/19
+46.02 (+33.75%)
since 12/10/18

Most Recent Stories

More News
BeiGene Announces Clinical Data on BRUKINSA(TM) (Zanubrutinib) at the 61st American Society of Hematology (ASH) Annual Meeting

Oral presentations on data from two clinical trials in chronic lymphocytic leukemia or small lymphocytic lymphoma

BGNE : 182.38 (-0.09%)
BGNE LOSS NOTICE: ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. - BGNE

Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of BeiGene, Ltd. (NASDAQ: BGNE) resulting from allegations that BeiGene...

BGNE : 182.38 (-0.09%)
BeiGene to Present at the 31st Annual Piper Jaffray Healthcare Conference

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment...

BGNE : 182.38 (-0.09%)
BeiGene Announces Clinical Data on Tislelizumab Presented at European Society for Medical Oncology (ESMO) Asia 2019 Congress

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment...

BGNE : 182.38 (-0.09%)
Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated Phase 1 data for single agent ZW25 in heavily pretreated patients...

BGNE : 182.38 (-0.09%)
ZYME : 42.20 (+6.40%)
U.S. FDA Grants BeiGene's BRUKINSA(TM) (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy

- This marks the first FDA approval for BeiGene

BGNE : 182.38 (-0.09%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE

Pomerantz LLP is investigating claims on behalf of investors of BeiGene, Ltd. ("BeiGene" or the "Company") (NASDAQ: BGNE). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

BGNE : 182.38 (-0.09%)
ROSEN, A LEADING GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. - BGNE

Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of BeiGene, Ltd. (NASDAQ: BGNE) resulting from allegations that BeiGene...

BGNE : 182.38 (-0.09%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE

Pomerantz LLP is investigating claims on behalf of investors of BeiGene, Ltd. ("BeiGene" or the "Company") (NASDAQ: BGNE). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

BGNE : 182.38 (-0.09%)
Bragar Eagel & Squire, P.C. Is Investigating Merit Medical Systems, Baxter International, Under Armour, and BeiGene on Behalf of Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims against Merit Medical Systems, Inc. (NASDAQ: MMSI), Baxter International, Inc. (NYSE: BAX),...

UA : 17.69 (unch)
UAA : 19.24 (-0.16%)
MMSI : 29.29 (-0.85%)
BAX : 82.29 (+0.91%)
BGNE : 182.38 (-0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade BGNE with:

Business Summary

BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.

See More

Key Turning Points

2nd Resistance Point 188.21
1st Resistance Point 185.30
Last Price 182.38
1st Support Level 179.53
2nd Support Level 176.67

See More

52-Week High 210.35
Last Price 182.38
Fibonacci 61.8% 171.25
Fibonacci 50% 159.18
Fibonacci 38.2% 147.10
52-Week Low 108.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar